Table 2.
Variables | All Patients (n = 38) | |||
---|---|---|---|---|
Unruptured VAP (n = 21) | Ruptured VAP (n = 17) | p-Value | ||
Etiology
|
16 (42.1%) 9 (23.7%) 12 (31.6%) 1 (2.6%) |
8 (38.1%) 6 (28.6%) 6 (28.6%) 1 (4.8%) |
8 (47.1%) 3 (17.6%) 6 (35.3%) 0 (0%) |
0.660 |
Site of the pseudoaneurysm
|
13 (34.2%) 7 (18.4%) 1 (2.6%) 4 (10.5%) 3 (7.9%) 4 (10.5%) 6 (15.8%) |
7 (33.3%) 4 (19%) 0 (0%) 3 (14.3%) 1 (4.8%) 2 (9.5%) 4 (19%) |
6 (35.3%) 3 (17.6%) 1 (5.9%) 1 (5.9%) 2 (11.8%) 2 (11.8%) 2 (11.8%) |
0.830 |
Endovascular treatment timing
|
14 (36.8%) 24 (63.2%) |
14 (66.7%) 7 (33.3%) |
0 (0%) 17 (100%) |
<0.001 |
|
18 (47.4%) 20 (52.6%) |
11 (52.4%) 10 (47.6%) |
7 (41.2%) 10 (58.8%) |
0.532 |
EVOH viscosity (centiStokes)
|
2 (5.3%) 6 (15.8%) 7 (18.4%) 23 (60.5%) |
1 (4.8%) 4 (19%) 2 (9.5%) 14 (66.7%) |
1 (5.9%) 2 (11.8%) 5 (29.4%) 9 (52.9%) |
0.449 |
Intraoperative contrast medium (mL) | 33.6 (±12) | 30.9 (±11.9) | 36.9 (±11.6) | 0.100 |
Volume of contrast to creatinine clearance ratio | 0.58 (±0.54) | 0.45 (±0.29) | 0.74 (±0.73) | 0.064 |
Vascular access site
|
34 (89.5%) 2 (5.3%) 2 (5.3%) |
18 (85.7%) 1 (4.8%) 2 (9.5%) |
16 (94.1%) 1 (5.9%) 0 (0%) |
0.424 |
Sheath diameter
|
7 (18.4%) 27 (71.1%) 4 (10.5%) |
4 (19%) 16 (76.2%) 1 (4.8%) |
3 (17.6%) 11 (64.7%) 3 (17.6%) |
0.435 |
CT-to-groin time (min) | 143.8 (±179) | 199.2 (±225.9) | 75.3 (±35.6) | 0.150 |
Procedure time (min) | 39.7 (±10.3) | 41 (±11.6) | 38.1 (±8.5) | 0.444 |
CT-to-embolization time (min) | 186.4 (±182.4) | 245.9 (±229) | 112.8 (±31.5) | 0.177 |
Fluoroscopy time (min) | 14.6 (±5.9) | 15.1 (±6) | 14 (±5.8) | 0.744 |
Cumulative air kerma (mGy) | 218 (±68.2) | 206.3 (±68.1) | 232.3 (±67.6) | 0.246 |
Dose area product (Gy/cm2) | 34.7 (±10.1) | 33.7 (±10) | 35.9 (±10.3) | 0.537 |
Abbreviations: VAP: Visceral Artery Pseudoaneurysm; PCNL: percutaneous nephrolithotomy; EVOH: ethylene-vinyl alcohol; CT: Computed Tomography.